127 related articles for article (PubMed ID: 36099549)
1. Growing Financial Burden From High-Cost Targeted Oral Anticancer Medicines Among Medicare Beneficiaries With Cancer.
Li M; Liao K; Pan IW; Shih YT
JCO Oncol Pract; 2022 Nov; 18(11):e1739-e1749. PubMed ID: 36099549
[TBL] [Abstract][Full Text] [Related]
2. Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries.
Shih YT; Xu Y; Liu L; Smieliauskas F
J Clin Oncol; 2017 Aug; 35(22):2482-2489. PubMed ID: 28471711
[TBL] [Abstract][Full Text] [Related]
3. Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications.
Shen C; Zhao B; Liu L; Shih YT
J Oncol Pract; 2017 Feb; 13(2):e152-e162. PubMed ID: 28095170
[TBL] [Abstract][Full Text] [Related]
4. Part D coverage gap reform: trends in drug use and expenditures.
Park J; Look KA
Am J Manag Care; 2020 Aug; 26(8):349-356. PubMed ID: 32835462
[TBL] [Abstract][Full Text] [Related]
5. Growing Number Of Unsubsidized Part D Beneficiaries With Catastrophic Spending Suggests Need For An Out-Of-Pocket Cap.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2018 Jul; 37(7):1048-1056. PubMed ID: 29985706
[TBL] [Abstract][Full Text] [Related]
6. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
[TBL] [Abstract][Full Text] [Related]
7. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
Glynn A; Hernandez I; Roberts ET
Health Serv Res; 2022 Oct; 57(5):1136-1144. PubMed ID: 35430735
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
9. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
[TBL] [Abstract][Full Text] [Related]
10. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
Park J; Look KA
Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
[TBL] [Abstract][Full Text] [Related]
11. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
Cortese BD; Dusetzina SB; Luckenbaugh AN; Al Hussein Al Awamlh B; Stimson CJ; Barocas DA; Penson DF; Chang SS; Talwar R
J Clin Oncol; 2023 Oct; 41(29):4664-4668. PubMed ID: 37290029
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.
Erath A; Dusetzina SB
JAMA Netw Open; 2020 Apr; 3(4):e203969. PubMed ID: 32338754
[TBL] [Abstract][Full Text] [Related]
13. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
14. Catastrophic Spending On Insulin In The United States, 2017-18.
Bakkila BF; Basu S; Lipska KJ
Health Aff (Millwood); 2022 Jul; 41(7):1053-1060. PubMed ID: 35787081
[TBL] [Abstract][Full Text] [Related]
15. Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D.
San-Juan-Rodriguez A; Good CB; Heyman RA; Parekh N; Shrank WH; Hernandez I
JAMA Neurol; 2019 Nov; 76(11):1386-1390. PubMed ID: 31449293
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
17. Coverage for hepatitis C drugs in Medicare Part D.
Jung JK; Feldman R; Cheong C; Du P; Leslie D
Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
[TBL] [Abstract][Full Text] [Related]
18. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
Dusetzina SB; Keating NL
J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
[TBL] [Abstract][Full Text] [Related]
19. Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study.
Safran DG; Strollo MK; Guterman S; Li A; Rogers WH; Neuman P
J Gen Intern Med; 2010 Jan; 25(1):10-7. PubMed ID: 19882193
[TBL] [Abstract][Full Text] [Related]
20. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
Li DG; Najafzadeh M; Kesselheim AS; Mostaghimi A
BMJ; 2019 Jul; 366():l4257. PubMed ID: 31315833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
